Delaware Senate Unanimously Passes Legislation to Ensure Patient Access to Interchangeable Biologic Medicines

The Biotechnology Industry Organization (BIO) and the Delaware BioScience Association (Delaware Bio) commend the Delaware State Senate for passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. “When they become available, these therapies will be safe, effective, and similar to innovator biologics. Furthermore, they will provide patients with more opportunities to address their unmet medical needs, particularly severely ill patients who rely on cutting-edge medical treatments.” The Delaware State Senate passed Senate Substitute 1 for Senate Bill 118 by a unanimous vote. The policies outlined in the bill align with BIO’s principles on biologic substitution, therefore BIO and Delaware Bio support passage of this bill as it moves for consideration by the Delaware House of Representatives. “Senate Bill 118 enjoys the support of a broad coalition of biologic and biosimilar manufacturers, along with industry, physician and patient groups,” said Jim Greenwood, BIO’s President and Chief Executive Officer. “This bill includes transparent communication on all biologic medicines dispensed in order to maintain a consistent and complete medical record. This legislation represents a significant step forward, ensures transparency and communication between patients and their treatment teams and is fully consistent with the BIO principles.”

Read the source article at

About the Author

Leave a Reply